Source comparison
Thymosin Alpha-1 Dosing and Administration Context: Week One Comparison
1.6 mg subcutaneous twice weekly CD4+ count increase 12–18%; modest NK activity boost None to minimal. Energy and infection resistance unchanged Standard research dose; biomarker shifts detectable but not yet functional 3.2 mg subcutaneous twice weekly CD4+ co
This comparison does not assign a generated winner or score.
- 1.6 mg subcutaneous twice weekly
- CD4+ count increase 12–18%; modest NK activity boost
- None to minimal. Energy and infection resistance unchanged
- Standard research dose; biomarker shifts detectable but not yet functional
- 3.2 mg subcutaneous twice weekly
- CD4+ count increase 15–22%; dendritic cell maturation markers elevated
- Rare reports of mild fatigue or injection site reaction; no immune function change
- Higher dose accelerates T-cell upregulation but doesn't compress the maturation timeline
- 1.6 mg daily (accelerated protocol)
- CD4+ count increase 20–25%; faster IL-2 and IFN-γ spike
- No meaningful symptom divergence from twice-weekly; slightly higher injection site sensitivity
- More frequent dosing increases biomarker magnitude but outcome timeline remains weeks 4–12
- Single 1.6 mg dose (one-time trial)
- Transient cytokine elevation; minimal sustained T-cell change
- None. Single dose insufficient for measurable immune remodeling
- Not therapeutically meaningful; Tα1 requires sustained administration